Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study

Introduction: The mainstay systemic treatment for non-oncogenic addictive advanced stage non-small cell lung cancer is chemotherapy. Anti-angiogenic agents are additive compounds that enhance disease control and lead to improvement of overall survival benefit. Recently PD-(L)1 blockage, a checkpoint...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Krittiya Korphaisarn, Pongwut Danchaivijitr, Thanyanan Reungwetwattana, Busayamas Chewaskulyong, Luangyot Thongthieang, Jarin Chindaprasirt, Kunlatida Maneenil, Chirawadee Sathitruangsak, Chanida Vinayanuwattikun
مؤلفون آخرون:	Siriraj Hospital
التنسيق:	مقال
منشور في:	2022
الموضوعات:	Biochemistry, Genetics and Molecular Biology Medicine
الوصول للمادة أونلاين:	https://repository.li.mahidol.ac.th/handle/123456789/76203
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer
بواسطة: Sumitra Thongprasert, وآخرون
منشور في: (2018)

COMBINATORIAL TARGETED THERAPY OF MAB AND NINTEDANIB ENHANCES CANCER CELL LETHALITY
بواسطة: TEO WAN CHING JOCELYN
منشور في: (2021)

Detection of aberrant SHP-1 promoter 2 methylation, an implication in advanced non-small cell lung cancer
بواسطة: Chanida Vinayanuwattikun
منشور في: (2010)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
بواسطة: Chaiyut Charoentum, وآخرون
منشور في: (2018)

Docetaxel Pharmacogenetics and its Influence on the Pharmacokinetics/Pharmacodynamics of Docetaxel in Asian Nasopharyngeal Cancer Patients
بواسطة: CHEW SIN CHI
منشور في: (2013)

Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202
بواسطة: Porntipa Korprasertthaworn, وآخرون
منشور في: (2020)

Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
بواسطة: Thongprasert S., وآخرون
منشور في: (2014)

Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
بواسطة: Huang, R.Y.-J, وآخرون
منشور في: (2020)

Cutaneous reaction associated with weekly docetaxel administration
بواسطة: Chew, L., وآخرون
منشور في: (2014)

Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
بواسطة: Suthinee Ithimakin, وآخرون
منشور في: (2020)

Docetaxel enhances lysosomal function through TFEB activation
بواسطة: Zhang J., وآخرون
منشور في: (2019)

Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: A multicenter analysis in Thailand
بواسطة: Nuttapong Ngamphaiboon, وآخرون
منشور في: (2020)

Benefits of prophylactic percutaneous gastrostomy in patients with nasopharyngeal cancer receiving concurrent chemoradiotherapy: A multicenter analysis
بواسطة: Tanadech Dechaphunkul, وآخرون
منشور في: (2022)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
بواسطة: Sun, B., وآخرون
منشور في: (2014)

Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel
بواسطة: Sun, B., وآخرون
منشور في: (2014)

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
بواسطة: Piyada Sitthideatphaiboon, وآخرون
منشور في: (2022)

Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
بواسطة: Goh, B.C., وآخرون
منشور في: (2014)

Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
بواسطة: Naiyarat Prasongsook, وآخرون
منشور في: (2022)

MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval
بواسطة: Thanyanan Reungwetwattana, وآخرون
منشور في: (2018)

Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancer
بواسطة: Charoentum C., وآخرون
منشور في: (2014)

Real-world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis
بواسطة: Arunee Dechaphunkul, وآخرون
منشور في: (2022)

Lung Cancer in Thailand
بواسطة: Thanyanan Reungwetwattana, وآخرون
منشور في: (2020)

Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
بواسطة: Thanyanan Reungwetwattana, وآخرون
منشور في: (2022)

Chemotherapy for non-small-cell lung carcinoma: From a blanket approach to individual therapy
بواسطة: Thanyanan Reungwetwattana, وآخرون
منشور في: (2018)

Nanomedicine: Enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation
بواسطة: Gan, C.W., وآخرون
منشور في: (2014)

Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
بواسطة: Raju, A., وآخرون
منشور في: (2014)

Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots
بواسطة: Muthu, M.S., وآخرون
منشور في: (2014)

Trastuzumab-conjugated vitamin e TPGS liposomes for sustained and targeted delivery of docetaxel
بواسطة: Raju, A., وآخرون
منشور في: (2014)

A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers
بواسطة: Yong, W.-P., وآخرون
منشور في: (2014)

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC)
بواسطة: Thanyanan Reungwetwattana, وآخرون
منشور في: (2018)

Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients
بواسطة: Sutima Luangdilok, وآخرون
منشور في: (2018)

Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
بواسطة: Nao Tagawa, وآخرون
منشور في: (2018)

Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel
بواسطة: Feng, S.-S., وآخرون
منشور في: (2014)

In Vitro and In Vivo Investigation of Nanoparticles of A Novel Copolymer for Substained and Controlled Delivery of Docetaxel
بواسطة: GAN CHEE WEE
منشور في: (2010)

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies
بواسطة: Goh, B.-C., وآخرون
منشور في: (2014)

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients
بواسطة: Millward, M.J., وآخرون
منشور في: (2016)

Effect of an education program on the prevention of ventilator-associated pneumonia: A multicenter study.
بواسطة: Somwang Danchaivijitr, وآخرون
منشور في: (2018)

In Vitro and In Vivo Study of Vitamin E TPGs Coated Immunoliposomes for Sustained and Targeted Delivery of Docetaxel
بواسطة: ANANDHKUMAR RAJU
منشور في: (2012)

Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinoma
بواسطة: Bantita Phruttinarakorn, وآخرون
منشور في: (2020)

Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: A randomised phase II study
بواسطة: Kei Siong Khoo, وآخرون
منشور في: (2018)